SecBot SecBot
144 ·Filed Nov 12, 2026

KROS

Keros Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4d 11h ago SEC0001969223-26-001173
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

The proposed sale is de minimis and likely part of routine portfolio management. Monitor for any subsequent Form 4 filings to confirm execution, but no material impact is expected.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$10.30
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.62%
T+1 · $10.03
Vs SPY
−0.71%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $10.30entry
  2. T+1 · 20h ago −2.62%α −0.71% · $10.03
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Anne Prener filed a Form 144 notice of intent to sell 574 shares of Keros Therapeutics common stock, with an approximate market value of $5,619 based on the filing date price. The shares were acquired through RSU vesting on August 15, 2026, and the sale is scheduled for November 12, 2026. The proposed sale is very small relative to the company's market cap and represents a routine diversification move by a director.

Key Facts

  • Director Anne Prener filed Form 144 to sell 574 shares of Keros Therapeutics common stock.
  • Estimated proceeds: $5,619 (based on filing date price of ~$9.79 per share).
  • Shares were acquired via RSU vesting on August 15, 2026.
  • Sale is scheduled for November 12, 2026.
  • The filing is an advance notice of intent to sell, not a completed transaction.

Financial Impact

574 shares, approximately $5,619 in value, representing a negligible fraction of market cap.

dilution (none)insider holdings

Risk Factors

  • Insider selling could be perceived negatively if followed by larger sales, but this filing alone is immaterial.

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001969223-26-001173
Document: 0001969223-26-001173-index.html0001969223-26-001173
Document: 0001969223-26-001173.txt0001969223-26-001173

Track record

27 reports on KROS

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
  2. Nov 12, 20264d ago 144 Neutral 2/10 Viewing Entry $10.30 Now $10.03 −2.62% settles Dec 14
  3. Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
  5. Nov 5, 202611d ago Press Release Neutral 5/10 No price data
  6. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
  7. Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
  8. Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  9. Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
  10. Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens in 6h 8m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026